BNP PARIBAS ARBITRAGE/CALL/PFIZER INC/30/0.1/21.06.24 Stock

Warrant

9ZLNB

NLBNPFR1WXF1

Market Closed - Euronext Paris 12:30:02 2024-05-22 pm EDT
0.055 EUR +120.00% Intraday chart for BNP PARIBAS ARBITRAGE/CALL/PFIZER INC/30/0.1/21.06.24
Current month+175.00%
1 month+120.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-05-22 0.055 +120.00%
24-05-21 0.025 0.00%
24-05-20 0.025 -28.57%
24-05-17 0.035 0.00%
24-05-16 0.035 -22.22%

Real-time Euronext Paris

Last update May 22, 2024 at 12:30 pm EDT

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying PFIZER, INC.
IssuerLogo Issuer BNP Paribas BNP Paribas
9ZLNB
ISINNLBNPFR1WXF1
Date issued 2023-12-15
Strike 30 $
Maturity 2024-06-21 (30 Days)
Parity 10 : 1
Emission price 0.08
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.245
Lowest since issue 0.01
Spread 0.01
Spread %16.67%

Company Profile

Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).
Sector
-
More about the company

Ratings for Pfizer, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Pfizer, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
28.56 USD
Average target price
31.94 USD
Spread / Average Target
+11.83%
Consensus
  1. Stock Market
  2. Warrants
  3. 9ZLNB Warrant
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW